Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Corgenix's lupus diagnostic:

This article was originally published in Clinica

Executive Summary

Corgenix Medical has received US 510(k) clearance of its IgG Anti-AtherOx test kit. It will be used in patients with systemic lupus erythematosus (SLE) and lupus-like disorders such as antiphospholipid syndrome, to assess their risk of vascular injuries or thrombosis. The test is already CE marked for use in the EU, and Denver, Colorado-based Corgenix said that it is now available worldwide. Studies have shown that measurement of the AtherOx antibody was significantly better than conventional anti-cardiolipin testing, the firm said.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel